Literature DB >> 25562264

Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010.

Shona J Livingstone1, Daniel Levin1, Helen C Looker1, Robert S Lindsay2, Sarah H Wild3, Nicola Joss4, Graham Leese5, Peter Leslie6, Rory J McCrimmon5, Wendy Metcalfe7, John A McKnight8, Andrew D Morris3, Donald W M Pearson9, John R Petrie2, Sam Philip9, Naveed A Sattar2, Jamie P Traynor7, Helen M Colhoun1.   

Abstract

IMPORTANCE: Type 1 diabetes has historically been associated with a significant reduction in life expectancy. Major advances in treatment of type 1 diabetes have occurred in the past 3 decades. Contemporary estimates of the effect of type 1 diabetes on life expectancy are needed.
OBJECTIVE: To examine current life expectancy in people with and without type 1 diabetes in Scotland. We also examined whether any loss of life expectancy in patients with type 1 diabetes is confined to those who develop kidney disease. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort of all individuals alive in Scotland with type 1 diabetes who were aged 20 years or older from 2008 through 2010 and were in a nationwide register (n=24,691 contributing 67,712 person-years and 1043 deaths). MAIN OUTCOMES AND MEASURES: Differences in life expectancy between those with and those without type 1 diabetes and the percentage of the difference due to various causes.
RESULTS: Life expectancy at an attained age of 20 years was an additional 46.2 years among men with type 1 diabetes and 57.3 years among men without it, an estimated loss in life expectancy with diabetes of 11.1 years (95% CI, 10.1-12.1). Life expectancy from age 20 years was an additional 48.1 years among women with type 1 diabetes and 61.0 years among women without it, an estimated loss with diabetes of 12.9 years (95% CI, 11.7-14.1). Even among those with type 1 diabetes with an estimated glomerular filtration rate of 90 mL/min/1.73 m2 or higher, life expectancy was reduced (49.0 years in men, 53.1 years in women) giving an estimated loss from age 20 years of 8.3 years (95% CI, 6.5-10.1) for men and 7.9 years (95% CI, 5.5-10.3) for women. Overall, the largest percentage of the estimated loss in life expectancy was related to ischemic heart disease (36% in men, 31% in women) but death from diabetic coma or ketoacidosis was associated with the largest percentage of the estimated loss occurring before age 50 years (29.4% in men, 21.7% in women). CONCLUSIONS AND RELEVANCE: Estimated life expectancy for patients with type 1 diabetes in Scotland based on data from 2008 through 2010 indicated an estimated loss of life expectancy at age 20 years of approximately 11 years for men and 13 years for women compared with the general population without type 1 diabetes.

Entities:  

Mesh:

Year:  2015        PMID: 25562264      PMCID: PMC4426486          DOI: 10.1001/jama.2014.16425

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  13 in total

1.  Methods of calculating deaths attributable to obesity.

Authors:  Katherine M Flegal; Barry I Graubard; David F Williamson
Journal:  Am J Epidemiol       Date:  2004-08-15       Impact factor: 4.897

2.  Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study.

Authors:  Christopher C Patterson; Gisela G Dahlquist; Eva Gyürüs; Anders Green; Gyula Soltész
Journal:  Lancet       Date:  2009-05-27       Impact factor: 79.321

3.  High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database.

Authors:  Sabita S Soedamah-Muthu; John H Fuller; Henrietta E Mulnier; Veena S Raleigh; Ross A Lawrenson; Helen M Colhoun
Journal:  Diabetes Care       Date:  2006-04       Impact factor: 19.112

4.  All-cause mortality in the Canterbury (New Zealand) insulin-treated Diabetic Registry population.

Authors:  L J Brown; R S Scott; C L Moir
Journal:  Diabetes Care       Date:  2001-01       Impact factor: 19.112

5.  In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study.

Authors:  T J Orchard; A M Secrest; R G Miller; T Costacou
Journal:  Diabetologia       Date:  2010-07-28       Impact factor: 10.122

6.  Time trends in mortality rates in type 1 diabetes from 2002 to 2011.

Authors:  Marit E Jørgensen; Thomas P Almdal; Bendix Carstensen
Journal:  Diabetologia       Date:  2013-08-16       Impact factor: 10.122

7.  Sedentary behaviour and life expectancy in the USA: a cause-deleted life table analysis.

Authors:  Peter T Katzmarzyk; I-Min Lee
Journal:  BMJ Open       Date:  2012-07-09       Impact factor: 2.692

8.  Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study.

Authors:  Shona J Livingstone; Helen C Looker; Eleanor J Hothersall; Sarah H Wild; Robert S Lindsay; John Chalmers; Stephen Cleland; Graham P Leese; John McKnight; Andrew D Morris; Donald W M Pearson; Norman R Peden; John R Petrie; Sam Philip; Naveed Sattar; Frank Sullivan; Helen M Colhoun
Journal:  PLoS Med       Date:  2012-10-02       Impact factor: 11.069

Review 9.  Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.

Authors:  Sarah D de Ferranti; Ian H de Boer; Vivian Fonseca; Caroline S Fox; Sherita Hill Golden; Carl J Lavie; Sheela N Magge; Nikolaus Marx; Darren K McGuire; Trevor J Orchard; Bernard Zinman; Robert H Eckel
Journal:  Diabetes Care       Date:  2014-08-11       Impact factor: 19.112

10.  Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort.

Authors:  Rachel G Miller; Aaron M Secrest; Ravi K Sharma; Thomas J Songer; Trevor J Orchard
Journal:  Diabetes       Date:  2012-07-30       Impact factor: 9.461

View more
  168 in total

1.  Assessing the Accuracy of Continuous Glucose Monitoring (CGM) Calibrated With Capillary Values Using Capillary or Venous Glucose Levels as a Reference.

Authors:  Mervi Andelin; Jort Kropff; Viktorija Matuleviciene; Jeffrey I Joseph; Stig Attvall; Elvar Theodorsson; Irl B Hirsch; Henrik Imberg; Sofia Dahlqvist; David Klonoff; Börje Haraldsson; J Hans DeVries; Marcus Lind
Journal:  J Diabetes Sci Technol       Date:  2016-06-28

2.  Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement.

Authors:  Stephen T Bartlett; James F Markmann; Paul Johnson; Olle Korsgren; Bernhard J Hering; David Scharp; Thomas W H Kay; Jonathan Bromberg; Jon S Odorico; Gordon C Weir; Nancy Bridges; Raja Kandaswamy; Peter Stock; Peter Friend; Mitsukazu Gotoh; David K C Cooper; Chung-Gyu Park; Phillip OʼConnell; Cherie Stabler; Shinichi Matsumoto; Barbara Ludwig; Pratik Choudhary; Boris Kovatchev; Michael R Rickels; Megan Sykes; Kathryn Wood; Kristy Kraemer; Albert Hwa; Edward Stanley; Camillo Ricordi; Mark Zimmerman; Julia Greenstein; Eduard Montanya; Timo Otonkoski
Journal:  Transplantation       Date:  2016-02       Impact factor: 4.939

3.  Substrate metabolism, hormone and cytokine levels and adipose tissue signalling in individuals with type 1 diabetes after insulin withdrawal and subsequent insulin therapy to model the initiating steps of ketoacidosis.

Authors:  Thomas S Voss; Mikkel H Vendelbo; Ulla Kampmann; Steen B Pedersen; Thomas S Nielsen; Mogens Johannsen; Mads V Svart; Niels Jessen; Niels Møller
Journal:  Diabetologia       Date:  2018-12-01       Impact factor: 10.122

4.  The role of proteomics in assessing beta-cell dysfunction and death in type 1 diabetes.

Authors:  Ernesto S Nakayasu; Wei-Jun Qian; Carmella Evans-Molina; Raghavendra G Mirmira; Decio L Eizirik; Thomas O Metz
Journal:  Expert Rev Proteomics       Date:  2019-06-24       Impact factor: 3.940

5.  Insulin: still a miracle after all these years.

Authors:  Fabrizio Barbetti; Simeon I Taylor
Journal:  J Clin Invest       Date:  2019-07-02       Impact factor: 14.808

Review 6.  Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.

Authors:  Alan Chait; Ira Goldberg
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

7.  Explaining the increased mortality in type 1 diabetes.

Authors:  Chiara Mameli; Sara Mazzantini; Moufida Ben Nasr; Paolo Fiorina; Andrea E Scaramuzza; Gian Vincenzo Zuccotti
Journal:  World J Diabetes       Date:  2015-07-10

8.  Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.

Authors:  Araz Rawshani; Naveed Sattar; Stefan Franzén; Aidin Rawshani; Andrew T Hattersley; Ann-Marie Svensson; Björn Eliasson; Soffia Gudbjörnsdottir
Journal:  Lancet       Date:  2018-08-09       Impact factor: 79.321

9.  Proinsulin C-peptide is an autoantigen in people with type 1 diabetes.

Authors:  Michelle So; Colleen M Elso; Eleonora Tresoldi; Miha Pakusch; Vimukthi Pathiraja; John M Wentworth; Leonard C Harrison; Balasubramanian Krishnamurthy; Helen E Thomas; Christine Rodda; Fergus J Cameron; Jacinta McMahon; Thomas W H Kay; Stuart I Mannering
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-01       Impact factor: 11.205

Review 10.  Cell Therapy for Type 1 Diabetes: Current and Future Strategies.

Authors:  Yasaman Aghazadeh; Maria Cristina Nostro
Journal:  Curr Diab Rep       Date:  2017-06       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.